ALFA FinderBSE filing, NSE: MANGALAM. Summary written from the filing by ALFA Finder's alert engine.
Mangalam Drugs and Organics Ltd: key numbers
- Share price
- ₹29.35
- Market cap
- ₹46.46 Cr
- Revenue (annual)
- ₹232.1 Cr
- Net profit (annual)
- ₹-44.40 Cr
- P/E (TTM)
- -1.2×Sector 43.4×
- Promoter holding
- 35.65%+0.00% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mangalam Drugs and Organics Ltd
All →Mangalam Drugs and Organics Q2 FY27 Results: Net Loss of ₹7.2 Cr, Loss Narrows
Mangalam Drugs and Organics Ltd reported revenue from operations of ₹79.4 Cr (+61.1% YoY) and a net loss of ₹7.2 Cr for Q2 FY27.
- Key figure
- Net loss ₹7.2 Cr
Mangalam Drugs and Organics Other Announcement
Mangalam Drugs & Organics Ltd has dispatched physical letters to shareholders without registered emails. These letters provide web-links to access the Annual Report for FY 2025-26.
Mangalam Drugs and Organics Management Change
Mangalam Drugs and Organics appointed Prabhakar Raghunath Zavar as Non-Executive Independent Director for 60 months, effective 15 September 2026. The disclosure covers a board-level appointment with a background profile and no monetary amount.
- Execution
- 60 months
Mangalam Drugs and Organics Board Meeting Date
Mangalam Drugs will hold a board meeting on 5 November 2026 to consider unaudited September 2026 quarter results. The agenda is proposed only, pending the meeting.
Mangalam Drugs and Organics Annual General Meeting
Mangalam Drugs issued a postal ballot notice seeking approval to re-appoint Praveen Saxena as independent director for a second five-year term. Voting closes 17 June 2026.
Mangalam Drugs and Organics Debt & Borrowing: ₹1,557 Cr
Mangalam Drugs and Organics Limited has reported a default amounting to Rs.1,557.27 Crore. The company has submitted a restructuring proposal to its banks to manage the obligation.
- Value
- ₹1,557 Cr
Other board meeting outcome announcements
All →Balmer Lawrie Investments Board Meeting Outcome
Balmer Lawrie Investments appointed M/s. K. K. Chanani & Associates as Statutory Auditor for FY 2026-27 under Section 139(5), per a C&AG letter. The appointment is effective from 10 November 2026.
- Execution
- FY 2026-27
Jiwanram Sheoduttrai Industries Board Meeting Outcome
Jiwanram Sheoduttrai's board approved convening its 29th AGM on 30 November 2026 and re-appointing a retiring non-executive director. The board also approved the FY2025-26 Board's Report.
Finolex Cables Board Meeting Outcome
Finolex Cables' board approved amending its insider trading code of conduct on 7 November 2026. Amended code was filed under PIT Regulation 8(2).
Chatterbox Technologies Board Meeting Outcome
Chatterbox's board approved a Rs. 7 crore related-party ceiling with its UAE subsidiary and a vendor change for IPO funds. Monitoring agency and deviation reports were also noted.
BCC Fuba India Board Meeting Outcome
BCC Fuba India's board met on November 6, 2026 and took note of consolidated related party transactions for the half year ended September 30, 2026. No financial results, capital raise or other material decision was reported.
Voltas Board Meeting Outcome
Voltas Limited's board approved Deloitte Haskins & Sells as statutory auditors for five years from the 73rd AGM, replacing SRBC & Co. LLP, whose second and final term ends at that AGM. Subject to shareholder approval.
- Execution
- Five years: financial years 2027-28 to 2031-32 (from the 73rd AGM in 2027 to the 78th AGM in 2032)